首页 > 最新文献

Multidisciplinary Respiratory Medicine最新文献

英文 中文
Impact of viral co-infection on clinical outcomes and mortality of COVID-19 patients: a study from Saudi Arabia. 病毒合并感染对COVID-19患者临床结局和死亡率的影响:来自沙特阿拉伯的一项研究
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2023-01-17 DOI: 10.4081/mrm.2023.915
Usama E Abu Elhassan, Saad M A Alqahtani, Naif S Al Saglan, Ali Hawan, Khadejah M Alshahrani, Hana S Al-Malih, Mohammed A Alshehri, Faisal S Alqahtani, Fatimah Alshomrani, Roaa S Almtheeb, Ibrahim H E Feteih, Magda S R Abdelwahab, Ibrahim M A Mahmoud

Background: In COVID-19 patients undetected co-infections may have severe clinical implications associated with prolonged hospitalization, ICU admission, and mortality. Therefore, we aimed to investigate the impact of viral coinfections on the outcomes of hospitalized patients with COVID-19 in a large tertiary Saudi Arabian Hospital.

Methods: A total of 178 adult patients with confirmed SARS-CoV-2 who were hospitalized at the Armed Forces Hospital Southern Region (AFHSR), Saudi Arabia, from March 1st to June 30th 2022, were enrolled. Real-time PCR for the detection of viral coinfections was carried out. Cases (SARS-CoV-2 with viral coinfections) and control (SARS-CoV-2 mono-infection) groups were compared.

Results: 12/178 (7%) of enrolled COVID-19 patients had viral coinfections. 82/178 (46%) of patients were males. 58% of patients had comorbidities. During the study period, 4/12 (33%) and 21/166 (13%) cases and control patients died, p=0.047, respectively. Duration of hospitalization was the only significant independent factor associated with SARS-CoV-2 coinfections, OR 1.140, 95% CI 1.020-1.274, p=0.021.

Conclusions: The findings of this study from a large tertiary Saudi Arabian Center revealed a prevalence of 7% for SARS-CoV-2 viral coinfections. SARS-CoV-2 coinfected patients had a significantly prolonged duration of hospitalization and higher mortality than those with SARS-CoV-2 alone. Future studies are needed.

背景:在COVID-19患者中,未被发现的合并感染可能具有严重的临床意义,与长期住院、ICU住院和死亡率相关。因此,我们的目的是研究病毒合并感染对沙特阿拉伯一家大型三级医院COVID-19住院患者预后的影响。方法:选取2022年3月1日至6月30日在沙特阿拉伯南部武装部队医院(AFHSR)住院的成年确诊SARS-CoV-2患者178例。采用实时荧光定量PCR检测病毒共感染。将病例(合并病毒感染的SARS-CoV-2)与对照组(单一感染的SARS-CoV-2)进行比较。结果:纳入的COVID-19患者中有12/178(7%)存在病毒合并感染。男性82/178(46%)。58%的患者有合并症。研究期间,4/12(33%)例死亡,21/166(13%)例死亡,p=0.047。住院时间是与SARS-CoV-2合并感染相关的唯一显著独立因素,OR为1.140,95% CI为1.020-1.274,p=0.021。结论:这项来自沙特阿拉伯一家大型三级中心的研究结果显示,SARS-CoV-2病毒合并感染的患病率为7%。与单独感染SARS-CoV-2的患者相比,合并感染SARS-CoV-2的患者住院时间明显延长,死亡率更高。需要进一步的研究。
{"title":"Impact of viral co-infection on clinical outcomes and mortality of COVID-19 patients: a study from Saudi Arabia.","authors":"Usama E Abu Elhassan,&nbsp;Saad M A Alqahtani,&nbsp;Naif S Al Saglan,&nbsp;Ali Hawan,&nbsp;Khadejah M Alshahrani,&nbsp;Hana S Al-Malih,&nbsp;Mohammed A Alshehri,&nbsp;Faisal S Alqahtani,&nbsp;Fatimah Alshomrani,&nbsp;Roaa S Almtheeb,&nbsp;Ibrahim H E Feteih,&nbsp;Magda S R Abdelwahab,&nbsp;Ibrahim M A Mahmoud","doi":"10.4081/mrm.2023.915","DOIUrl":"https://doi.org/10.4081/mrm.2023.915","url":null,"abstract":"<p><strong>Background: </strong>In COVID-19 patients undetected co-infections may have severe clinical implications associated with prolonged hospitalization, ICU admission, and mortality. Therefore, we aimed to investigate the impact of viral coinfections on the outcomes of hospitalized patients with COVID-19 in a large tertiary Saudi Arabian Hospital.</p><p><strong>Methods: </strong>A total of 178 adult patients with confirmed SARS-CoV-2 who were hospitalized at the Armed Forces Hospital Southern Region (AFHSR), Saudi Arabia, from March 1<sup>st</sup> to June 30<sup>th</sup> 2022, were enrolled. Real-time PCR for the detection of viral co<i>‑</i>infections was carried out. Cases (SARS-CoV-2 with viral coinfections) and control (SARS-CoV-2 mono-infection) groups were compared.</p><p><strong>Results: </strong>12/178 (7%) of enrolled COVID-19 patients had viral coinfections. 82/178 (46%) of patients were males. 58% of patients had comorbidities. During the study period, 4/12 (33%) and 21/166 (13%) cases and control patients died, p=0.047, respectively. Duration of hospitalization was the only significant independent factor associated with SARS-CoV-2 coinfections, OR 1.140, 95% CI 1.020-1.274, p=0.021.</p><p><strong>Conclusions: </strong>The findings of this study from a large tertiary Saudi Arabian Center revealed a prevalence of 7% for SARS-CoV-2 viral coinfections. SARS-CoV-2 coinfected patients had a significantly prolonged duration of hospitalization and higher mortality than those with SARS-CoV-2 alone. Future studies are needed.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 1","pages":"915"},"PeriodicalIF":2.3,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/d1/mrm-18-1-915.PMC10230552.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9571931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of the 4C ISARIC mortality score in hospitalized COVID-19 patients at a large tertiary Saudi Arabian center. 4C ISARIC死亡率评分在沙特阿拉伯一家大型三级医疗中心住院的COVID-19患者中的应用
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2023-01-17 DOI: 10.4081/mrm.2023.917
Usama E Abu Elhassan, Saad M A Alqahtani, Naif S Al Saglan, Ali Hawan, Faisal S Alqahtani, Roaa S Almtheeb, Magda S R Abdelwahab, Mohammed A AlFlan, Abdulaziz S Y Alfaifi, Mohammed A Alqahtani, Fawwaz A Alshafa, Ali A Alsalem, Yahya A Al-Imamah, Omar S A Abdelwahab, Mohammed F Attia, Ibrahim M A Mahmoud

Background: The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) 4C mortality score has been used before as a valuable tool for predicting mortality in COVID-19 patients. We aimed to address the utility of the 4C score in a well-defined Saudi population with COVID-19 admitted to a large tertiary referral hospital in Saudi Arabia.

Methods: A retrospective study was conducted that included all adults COVID19 patients admitted to the Armed Forces Hospital Southern Region (AFHSR), between January 2021 and September 2022. The receiver operating characteristic (ROC) curve depicted the diagnostic performance of the 4C Score for mortality prediction.

Results: A total of 1,853 patients were enrolled. The ROC curve of the 4C score had an area under the curve of 0.73 (95% CI: 0.702-0.758), p<0.001. The sensitivity and specificity with scores >8 were 80% and 58%, respectively, the positive and negative predictive values were 28% and 93%, respectively. Three hundred and sixteen (17.1%), 638 (34.4%), 814 (43.9%), and 85 (4.6%) patients had low, intermediate, high, and very high values, respectively. There were significant differences between survivors and non-survivors with regard to all variables used in the calculation of the 4C score. Multivariable logistic regression analysis revealed that all components of the 4C score, except gender and O2 saturation, were independent significant predictors of mortality.

Conclusions: Our data support previous international and Saudi studies that the 4C mortality score is a reliable tool with good sensitivity and specificity in the mortality prediction of COVID-19 patients. All components of the 4C score, except gender and O2 saturation, were independent significant predictors of mortality. Within the 4C score, odds ratios increased proportionately with an increase in the score value. Future multi-center prospective studies are warranted.

背景:国际严重急性呼吸道和新发感染联盟(ISARIC) 4C死亡率评分之前已被用作预测COVID-19患者死亡率的有价值工具。我们的目的是解决4C评分在沙特阿拉伯一家大型三级转诊医院入院的明确定义的沙特COVID-19患者中的效用。方法:对2021年1月至2022年9月期间在南部地区武装部队医院(AFHSR)住院的所有成年COVID - 19患者进行了回顾性研究。受试者工作特征(ROC)曲线描述4C评分对死亡率预测的诊断性能。结果:共纳入1853例患者。4C评分的ROC曲线下面积为0.73 (95% CI: 0.702 ~ 0.758), p8分别为80%和58%,阳性预测值和阴性预测值分别为28%和93%。316例(17.1%)、638例(34.4%)、814例(43.9%)和85例(4.6%)患者分别为低值、中值、高值和极高值。在计算4C评分时使用的所有变量方面,幸存者和非幸存者之间存在显著差异。多变量logistic回归分析显示,除性别和氧饱和度外,4C评分的所有组成部分都是死亡率的独立显著预测因子。结论:我们的数据支持先前的国际和沙特研究,4C死亡率评分是预测COVID-19患者死亡率的可靠工具,具有良好的敏感性和特异性。除性别和氧饱和度外,4C评分的所有组成部分都是死亡率的独立显著预测因子。在4C评分范围内,优势比随着分值的增加成比例地增加。未来的多中心前瞻性研究是必要的。
{"title":"Utility of the 4C ISARIC mortality score in hospitalized COVID-19 patients at a large tertiary Saudi Arabian center.","authors":"Usama E Abu Elhassan,&nbsp;Saad M A Alqahtani,&nbsp;Naif S Al Saglan,&nbsp;Ali Hawan,&nbsp;Faisal S Alqahtani,&nbsp;Roaa S Almtheeb,&nbsp;Magda S R Abdelwahab,&nbsp;Mohammed A AlFlan,&nbsp;Abdulaziz S Y Alfaifi,&nbsp;Mohammed A Alqahtani,&nbsp;Fawwaz A Alshafa,&nbsp;Ali A Alsalem,&nbsp;Yahya A Al-Imamah,&nbsp;Omar S A Abdelwahab,&nbsp;Mohammed F Attia,&nbsp;Ibrahim M A Mahmoud","doi":"10.4081/mrm.2023.917","DOIUrl":"https://doi.org/10.4081/mrm.2023.917","url":null,"abstract":"<p><strong>Background: </strong>The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) 4C mortality score has been used before as a valuable tool for predicting mortality in COVID-19 patients. We aimed to address the utility of the 4C score in a well-defined Saudi population with COVID-19 admitted to a large tertiary referral hospital in Saudi Arabia.</p><p><strong>Methods: </strong>A retrospective study was conducted that included all adults COVID<b>‑</b>19 patients admitted to the Armed Forces Hospital Southern Region (AFHSR), between January 2021 and September 2022. The receiver operating characteristic (ROC) curve depicted the diagnostic performance of the 4C Score for mortality prediction.</p><p><strong>Results: </strong>A total of 1,853 patients were enrolled. The ROC curve of the 4C score had an area under the curve of 0.73 (95% CI: 0.702-0.758), p<0.001. The sensitivity and specificity with scores >8 were 80% and 58%, respectively, the positive and negative predictive values were 28% and 93%, respectively. Three hundred and sixteen (17.1%), 638 (34.4%), 814 (43.9%), and 85 (4.6%) patients had low, intermediate, high, and very high values, respectively. There were significant differences between survivors and non-survivors with regard to all variables used in the calculation of the 4C score. Multivariable logistic regression analysis revealed that all components of the 4C score, except gender and O<sub>2</sub> saturation, were independent significant predictors of mortality.</p><p><strong>Conclusions: </strong>Our data support previous international and Saudi studies that the 4C mortality score is a reliable tool with good sensitivity and specificity in the mortality prediction of COVID-19 patients. All components of the 4C score, except gender and O<sub>2</sub> saturation, were independent significant predictors of mortality. Within the 4C score, odds ratios increased proportionately with an increase in the score value. Future multi-center prospective studies are warranted.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 ","pages":"917"},"PeriodicalIF":2.3,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/b2/mrm-18-1-917.PMC10483479.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10221798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of secondary pneumothorax due to multiple pulmonary metastases of granulosa cell tumor. 一例颗粒细胞瘤多发性肺转移导致的继发性气胸。
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2022-12-05 eCollection Date: 2022-01-12 DOI: 10.4081/mrm.2022.884
Tetsuya Yamagishi, Masashi Matsuyama, Ryo Watanabe, Chio Sakai, Sosuke Matsumura, Masayuki Nakajima, Shinji Kikuchi, Noriaki Sakamoto, Yukio Sato, Nobuyuki Hizawa

Introduction: Ovarian granulosa cell tumor is a relatively rare tumor that accounts for 2-5% of malignant ovarian tumors. This tumor progresses slowly and may recur late in life.

Case presentation: A 70-year-old woman was admitted to our hospital with a left secondary pneumothorax due to metastatic lung tumors of granulosa cell tumor. Reports of secondary pneumothorax due to granulosa cell tumor are rare. Thoracoscopic suturing and pleurodesis using talc were effective in the treatment of this pneumothorax.

Conclusions: We experienced a rare case of secondary pneumothorax due to multiple pulmonary metastases of granulosa cell tumor. It should be noted that pulmonary metastasis of granulosa cell tumor can lead to secondary pneumothorax.

引言卵巢颗粒细胞瘤是一种相对罕见的肿瘤,占恶性卵巢肿瘤的 2-5%。这种肿瘤进展缓慢,可能在晚期复发:一位 70 岁的女性因颗粒细胞瘤转移至肺部导致左侧继发性气胸而入院。颗粒细胞瘤导致继发性气胸的报道非常罕见。胸腔镜缝合术和使用滑石粉的胸膜穿刺术对治疗该气胸很有效:我们经历了一例罕见的颗粒细胞瘤多发性肺转移导致的继发性气胸。应注意的是,颗粒细胞瘤的肺转移可导致继发性气胸。
{"title":"A case of secondary pneumothorax due to multiple pulmonary metastases of granulosa cell tumor.","authors":"Tetsuya Yamagishi, Masashi Matsuyama, Ryo Watanabe, Chio Sakai, Sosuke Matsumura, Masayuki Nakajima, Shinji Kikuchi, Noriaki Sakamoto, Yukio Sato, Nobuyuki Hizawa","doi":"10.4081/mrm.2022.884","DOIUrl":"10.4081/mrm.2022.884","url":null,"abstract":"<p><strong>Introduction: </strong>Ovarian granulosa cell tumor is a relatively rare tumor that accounts for 2-5% of malignant ovarian tumors. This tumor progresses slowly and may recur late in life.</p><p><strong>Case presentation: </strong>A 70-year-old woman was admitted to our hospital with a left secondary pneumothorax due to metastatic lung tumors of granulosa cell tumor. Reports of secondary pneumothorax due to granulosa cell tumor are rare. Thoracoscopic suturing and pleurodesis using talc were effective in the treatment of this pneumothorax.</p><p><strong>Conclusions: </strong>We experienced a rare case of secondary pneumothorax due to multiple pulmonary metastases of granulosa cell tumor. It should be noted that pulmonary metastasis of granulosa cell tumor can lead to secondary pneumothorax.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"17 1","pages":"884"},"PeriodicalIF":2.0,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/26/mrm-17-1-884.PMC9796701.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10457819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney and lung in pathology: mechanisms and clinical implications. 肾和肺病理:机制和临床意义。
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2022-01-18 eCollection Date: 2022-01-12 DOI: 10.4081/mrm.2022.819
Ersilia Satta, Carmelo Alfarone, Alfonso De Maio, Sandro Gentile, Carmine Romano, Mario Polverino, Francesca Polverino

There is a close, physiological, relationship between kidney and lung that begin in the fetal age, and is aimed to keep homeostatic balance in the body. From a pathological point of view, the kidneys could be damaged by inflammatory mediators or by immune-mediated factors linked to a primary lung disease or, conversely, it could be the kidney disease that causes lung damage. Non-immunological mechanisms are frequently involved in renal and pulmonary diseases, as observed in chronic conditions. This crosstalk have clinical and therapeutic consequences. This review aims to describe the pulmonary-renal link in physiology and in pathological conditions.

肾和肺在胎儿时期就开始了密切的生理关系,目的是保持体内的稳态平衡。从病理学角度来看,肾脏可能受到炎症介质或与原发性肺部疾病相关的免疫介导因子的损害,或者相反,可能是肾脏疾病导致肺损伤。非免疫机制经常涉及肾脏和肺部疾病,正如在慢性疾病中观察到的那样。这种相声具有临床和治疗意义。这篇综述的目的是描述生理和病理条件下的肺肾联系。
{"title":"Kidney and lung in pathology: mechanisms and clinical implications.","authors":"Ersilia Satta,&nbsp;Carmelo Alfarone,&nbsp;Alfonso De Maio,&nbsp;Sandro Gentile,&nbsp;Carmine Romano,&nbsp;Mario Polverino,&nbsp;Francesca Polverino","doi":"10.4081/mrm.2022.819","DOIUrl":"https://doi.org/10.4081/mrm.2022.819","url":null,"abstract":"<p><p>There is a close, physiological, relationship between kidney and lung that begin in the fetal age, and is aimed to keep homeostatic balance in the body. From a pathological point of view, the kidneys could be damaged by inflammatory mediators or by immune-mediated factors linked to a primary lung disease or, conversely, it could be the kidney disease that causes lung damage. Non-immunological mechanisms are frequently involved in renal and pulmonary diseases, as observed in chronic conditions. This crosstalk have clinical and therapeutic consequences. This review aims to describe the pulmonary-renal link in physiology and in pathological conditions.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"17 2","pages":"819"},"PeriodicalIF":2.3,"publicationDate":"2022-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/31/mrm-17-1-819.PMC8791019.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39894452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Awareness towards the main ILD among primary care physicians 初级保健医生对主要ILD的认识
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2022-01-12 DOI: 10.4081/mrm.2022.848
M. Silva, Amélia Fernandes, Ana Rita Pereira, Sofia Madanelo, Tatiana Clemêncio, P. Ferreira
Background Interstitial lung diseases (ILDs) comprise a group of multiple entities sharing some clinical, functional, and radiological similarities. In many countries primary care setting has been devoid of pre- and post-graduate educational interventions focused on basic knowledge on ILD. This, along with usual nonspecificity of symptoms at presentation, may contribute to diagnostic delay in this disease setting. Methods We designed a study questionnaire to assess the level of awareness on basic diagnostic and management aspects of core ILDs – idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, sarcoidosis, connective tissue disease related-ILD, and drug-induced ILD - among primary care physicians (GPs) from five “ACeS Baixo Vouga” health centres and to perceive possible weaknesses. Differences in awareness between GPs under 45 and over 45 yearsold were also assessed. Results Globally, 69% of questions were correctly answered but only 21.9% of GPs considered to have a satisfactory self-perceived level of knowledge on ILD. Except sarcoidosis (p=0.017) and some isolated questions on other diseases, no significant differences were found between physicians below 45 years and above. Though, there was a trend to higher awareness in the younger group. The best awareness was seen in sarcoidosis. IPF questions had the worst performance and only 48.5% of GPs recognized the importance of velcro-type crackles in suggesting a possible diagnosis. Conclusion Specific attention should be devoted to educational interventions directed to GPs on basic notions on the main ILDs. This could improve the usual diagnostic delay in many ILDs, as a timely diagnosis is essential for an early treatment and prolonged patient survival.
背景:间质性肺疾病(ILDs)包括一组具有一些临床、功能和放射学相似性的多种实体。在许多国家,初级保健机构缺乏针对ILD基础知识的研究生前和研究生教育干预。这一点,再加上通常表现时症状的非特异性,可能导致这种疾病的诊断延迟。方法:我们设计了一份研究问卷,评估5个“ACeS Baixo Vouga”卫生中心的初级保健医生(gp)对核心ILD(特发性肺纤维化(IPF)、超敏性肺炎、结节病、结缔组织病相关ILD和药物性ILD)基本诊断和管理方面的认识水平,并发现可能存在的不足。还评估了45岁以下和45岁以上的全科医生在认知方面的差异。结果在全球范围内,69%的问题被正确回答,但只有21.9%的全科医生认为对ILD有满意的自我认知水平。除结节病(p=0.017)和其他疾病的个别问题外,45岁以下医师与45岁以上医师之间无显著差异。不过,年轻群体的意识有提高的趋势。结节病的意识最强。IPF问题表现最差,只有48.5%的全科医生认识到魔术贴式裂纹在建议可能诊断中的重要性。结论应特别重视对全科医生的教育干预,使他们了解主要疾病的基本概念。这可以改善许多ild通常的诊断延迟,因为及时诊断对于早期治疗和延长患者生存至关重要。
{"title":"Awareness towards the main ILD among primary care physicians","authors":"M. Silva, Amélia Fernandes, Ana Rita Pereira, Sofia Madanelo, Tatiana Clemêncio, P. Ferreira","doi":"10.4081/mrm.2022.848","DOIUrl":"https://doi.org/10.4081/mrm.2022.848","url":null,"abstract":"Background Interstitial lung diseases (ILDs) comprise a group of multiple entities sharing some clinical, functional, and radiological similarities. In many countries primary care setting has been devoid of pre- and post-graduate educational interventions focused on basic knowledge on ILD. This, along with usual nonspecificity of symptoms at presentation, may contribute to diagnostic delay in this disease setting. Methods We designed a study questionnaire to assess the level of awareness on basic diagnostic and management aspects of core ILDs – idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, sarcoidosis, connective tissue disease related-ILD, and drug-induced ILD - among primary care physicians (GPs) from five “ACeS Baixo Vouga” health centres and to perceive possible weaknesses. Differences in awareness between GPs under 45 and over 45 yearsold were also assessed. Results Globally, 69% of questions were correctly answered but only 21.9% of GPs considered to have a satisfactory self-perceived level of knowledge on ILD. Except sarcoidosis (p=0.017) and some isolated questions on other diseases, no significant differences were found between physicians below 45 years and above. Though, there was a trend to higher awareness in the younger group. The best awareness was seen in sarcoidosis. IPF questions had the worst performance and only 48.5% of GPs recognized the importance of velcro-type crackles in suggesting a possible diagnosis. Conclusion Specific attention should be devoted to educational interventions directed to GPs on basic notions on the main ILDs. This could improve the usual diagnostic delay in many ILDs, as a timely diagnosis is essential for an early treatment and prolonged patient survival.","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42323820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Monitoring daily symptoms and (self-reported) exacerbations in patients with bronchiectasis: a prospective study. 监测支气管扩张患者的日常症状和(自我报告的)恶化:一项前瞻性研究
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2022-01-12 DOI: 10.4081/mrm.2022.859
Jéssica de Campos Medeiros, Ádria Cristina da Silva, Mônica Corso Pereira

Background: Exacerbations are pivotal events in the natural history of patients with non-cystic fibrosis bronchiectasis (NCFB), since they have a negative impact on the functional evolution of these individuals. The daily symptoms of patients with NCFB show great variability, which negatively affects their self-perception of symptoms and exacerbations. The aim of this study was to identify daily symptoms in patients with NCFB, and to investigate whether there is a correlation between the frequency of self-reported exacerbations and events defined according to the criteria established in the literature to define exacerbation in bronchiectasis.

Methods: This observational and prospective study was carried out in outpatient clinics of a Brazilian public university hospital. Over 24 weeks, patients completed a diary in which daily symptoms, self-reported exacerbations, and demands for medical care for respiratory symptoms were recorded. The instrument used (diary and symptom scores ranging from 0 to 12) were developed by the researchers. The participants also answered questionnaires mMRC, Leicester's, and St. George's Respiratory (SGRQ).

Results: Twenty-eight patients returned the diary, their mean age was 54 years, and 50% out of them were classified as mild by the FACED score. Cough (64%) and expectoration (62%) were the most frequent symptoms. Correlations were found between the stability score and the mMRC (r=0.4727, p=0.011) and SGRQ (r=0.6748, p<0.0001) questionnaires. The number of self-perceived exacerbations (24) was significantly lower than exacerbations using the exacerbation consensus (63) (p<0.01). Additionally, no correlation was found between these two criteria.

Conclusions: There was great variability of symptoms among the individuals sampled, and even for the same individual, over time. Patients had low self-perception of exacerbations, which suggests that strategies aimed at improving this self-perception may contribute to the early detection of exacerbations.

背景:急性加重是非囊性纤维化支气管扩张(NCFB)患者自然史中的关键事件,因为它们对这些个体的功能进化有负面影响。NCFB患者的日常症状表现出很大的变异性,这对他们对症状和恶化的自我感知产生了负面影响。本研究的目的是确定NCFB患者的日常症状,并调查自我报告的加重频率与根据文献中建立的定义支气管扩张加重的标准定义的事件之间是否存在相关性。方法:这项观察性和前瞻性研究在巴西公立大学医院的门诊进行。在24周的时间里,患者完成了一份日记,其中记录了日常症状、自我报告的恶化情况以及对呼吸道症状的医疗护理需求。使用的工具(日记和症状评分范围从0到12)是由研究人员开发的。参与者还回答了mMRC、莱斯特和圣乔治呼吸系统问卷(SGRQ)。结果:28例患者归还日记,平均年龄54岁,其中50%的患者按照face评分分为轻度。咳嗽(64%)和咳痰(62%)是最常见的症状。稳定性评分与mMRC (r=0.4727, p=0.011)和SGRQ (r=0.6748, p)之间存在相关性。结论:随着时间的推移,样本个体之间的症状存在很大差异,即使是同一个体。患者对病情恶化的自我知觉较低,这表明旨在改善这种自我知觉的策略可能有助于早期发现病情恶化。
{"title":"Monitoring daily symptoms and (self-reported) exacerbations in patients with bronchiectasis: a prospective study.","authors":"Jéssica de Campos Medeiros,&nbsp;Ádria Cristina da Silva,&nbsp;Mônica Corso Pereira","doi":"10.4081/mrm.2022.859","DOIUrl":"https://doi.org/10.4081/mrm.2022.859","url":null,"abstract":"<p><strong>Background: </strong>Exacerbations are pivotal events in the natural history of patients with non-cystic fibrosis bronchiectasis (NCFB), since they have a negative impact on the functional evolution of these individuals. The daily symptoms of patients with NCFB show great variability, which negatively affects their self-perception of symptoms and exacerbations. The aim of this study was to identify daily symptoms in patients with NCFB, and to investigate whether there is a correlation between the frequency of self-reported exacerbations and events defined according to the criteria established in the literature to define exacerbation in bronchiectasis.</p><p><strong>Methods: </strong>This observational and prospective study was carried out in outpatient clinics of a Brazilian public university hospital. Over 24 weeks, patients completed a diary in which daily symptoms, self-reported exacerbations, and demands for medical care for respiratory symptoms were recorded. The instrument used (diary and symptom scores ranging from 0 to 12) were developed by the researchers. The participants also answered questionnaires mMRC, Leicester's, and St. George's Respiratory (SGRQ).</p><p><strong>Results: </strong>Twenty-eight patients returned the diary, their mean age was 54 years, and 50% out of them were classified as mild by the FACED score. Cough (64%) and expectoration (62%) were the most frequent symptoms. Correlations were found between the stability score and the mMRC (r=0.4727, p=0.011) and SGRQ (r=0.6748, p<0.0001) questionnaires. The number of self-perceived exacerbations (24) was significantly lower than exacerbations using the exacerbation consensus (63) (p<0.01). Additionally, no correlation was found between these two criteria.</p><p><strong>Conclusions: </strong>There was great variability of symptoms among the individuals sampled, and even for the same individual, over time. Patients had low self-perception of exacerbations, which suggests that strategies aimed at improving this self-perception may contribute to the early detection of exacerbations.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"17 1","pages":"859"},"PeriodicalIF":2.3,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/9d/mrm-17-1-859.PMC9761409.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10425071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of Pneumocystis jirovecii pneumonia in a patient with acquired immune deficiency syndrome who showed eosinophilia and an increased serum TARC/CCL17 level. 一例获得性免疫缺陷综合征患者的乙基肺囊虫肺炎,表现为嗜酸性粒细胞增多和血清TARC/CCL17水平升高。
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2022-01-12 DOI: 10.4081/mrm.2022.802
Yuki Yabuuchi, Masashi Matsuyama, Sosuke Matsumura, Masayuki Nakajima, Yoshihiko Kiyasu, Yuto Takeuchi, Yoshihiko Murata, Ryota Matsuoka, Masayuki Noguchi, Nobuyuki Hizawa

Pneumocystis jirovecii pneumonia (PCP) in patients with acquired immune deficiency syndrome (AIDS) shows eosinophilic pneumonia like condition. The detailed mechanisms how AIDS-associated PCP causes eosinophilic pneumonia has not been elucidated, but it has been suggested that beta-D-glucan, a major component of Pneumocystis jirovecii, and T helper type 2 immunity may be involved in the mechanism of eosinophilia in the lung. We experienced the case who developed an eosinophilic pneumonia-like condition in a patient with AIDS-associated PCP, whose clinical course indicated the importance of TARC/CCL17 but not IL-4 and IL-5 as involved in eosinophilia caused by HIV and Pneumocystis jirovecii infection.

获得性免疫缺陷综合征(AIDS)患者的乙基肺囊虫肺炎(PCP)表现为嗜酸性肺炎样症状。艾滋病相关PCP引起嗜酸性粒细胞肺炎的详细机制尚未阐明,但有研究表明,乙型肺囊虫的主要成分β - d -葡聚糖和T辅助2型免疫可能参与了肺嗜酸性粒细胞增多的机制。我们经历了一个艾滋病相关PCP患者出现嗜酸性肺炎样疾病的病例,其临床病程表明TARC/CCL17而不是IL-4和IL-5在HIV和乙氏肺囊虫感染引起的嗜酸性粒细胞增多症中的重要性。
{"title":"A case of <i>Pneumocystis jirovecii</i> pneumonia in a patient with acquired immune deficiency syndrome who showed eosinophilia and an increased serum TARC/CCL17 level.","authors":"Yuki Yabuuchi,&nbsp;Masashi Matsuyama,&nbsp;Sosuke Matsumura,&nbsp;Masayuki Nakajima,&nbsp;Yoshihiko Kiyasu,&nbsp;Yuto Takeuchi,&nbsp;Yoshihiko Murata,&nbsp;Ryota Matsuoka,&nbsp;Masayuki Noguchi,&nbsp;Nobuyuki Hizawa","doi":"10.4081/mrm.2022.802","DOIUrl":"https://doi.org/10.4081/mrm.2022.802","url":null,"abstract":"<p><p><i>Pneumocystis jirovecii</i> pneumonia (PCP) in patients with acquired immune deficiency syndrome (AIDS) shows eosinophilic pneumonia like condition. The detailed mechanisms how AIDS-associated PCP causes eosinophilic pneumonia has not been elucidated, but it has been suggested that beta-D-glucan, a major component of <i>Pneumocystis jirovecii</i>, and T helper type 2 immunity may be involved in the mechanism of eosinophilia in the lung. We experienced the case who developed an eosinophilic pneumonia-like condition in a patient with AIDS-associated PCP, whose clinical course indicated the importance of TARC/CCL17 but not IL-4 and IL-5 as involved in eosinophilia caused by HIV and <i>Pneumocystis jirovecii</i> infection.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"17 2","pages":"802"},"PeriodicalIF":2.3,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/02/mrm-17-2-802.PMC8764545.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39894451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Tracheostomy healing time after decannulation 气管切开取管后愈合时间
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2022-01-12 DOI: 10.4081/mrm.2022.822
K. J. Christiansen, Louise Devantier, T. Pasgaard, T. Benson, Johanne Juel Petersen, T. Kjærgaard, Michael Pedersen
Background Prolonged healing of tracheostomy after decannulation has a negative impact on respiration, hygiene, cosmetics, and social life. Even so, evidence-based observations of tracheostoma healing time are lacking. Therefore, the aim of this study was to determine tracheostomy wound healing time after decannulation. Methods In this prospective observational cohort study, we included 30 subjects undergoing decannulation following prolonged mechanical ventilation via tracheostomy. Our primary endpoint was tracheostomy healing time defined as time from decannulation to airtight healing. To identify any factors related to healing time, we included information about patient demographics, comorbidities, tracheostomy method, tube size, and intubation time. All subjects were observed daily until their tracheostomy wound had healed. Results The median tracheostomy healing time was 6.5 (1-22) days. The duration of tracheal cannulation was the only factor significantly correlated with prolonged healing (p=0.03). Four patients were subjected to recannulation shortly after decannulation due to hypercapnia, respiratory failure, secretion accumulation, or self-decannulation. All wounds achieved complete spontaneous airtight closure. Conclusions Duration of spontaneous tracheostomy closure after decannulation was 1-22 days, and closure time correlated with duration of cannulation.
背景拔管后气管造口术的长期愈合对呼吸、卫生、化妆品和社交生活都有负面影响。即便如此,仍缺乏对气管造口愈合时间的循证观察。因此,本研究的目的是确定拔管后气管造口术伤口的愈合时间。方法在这项前瞻性观察性队列研究中,我们纳入了30名通过气管造口术进行长时间机械通气后进行拔管的受试者。我们的主要终点是气管造口术的愈合时间,定义为从拔管到气密愈合的时间。为了确定与愈合时间相关的任何因素,我们纳入了有关患者人口统计、合并症、气管造口术方法、导管尺寸和插管时间的信息。每天观察所有受试者,直到他们的气管造口伤口愈合。结果气管造口术中位愈合时间为6.5(1-22)天。气管插管的持续时间是唯一与愈合延长显著相关的因素(p=0.03)。4名患者在拔管后不久因高碳酸血症、呼吸衰竭、分泌物积聚或自行拔管而再次插管。所有伤口都实现了完全自发的气密闭合。结论拔管后自然气管造口术的闭合时间为1-22天,闭合时间与插管时间相关。
{"title":"Tracheostomy healing time after decannulation","authors":"K. J. Christiansen, Louise Devantier, T. Pasgaard, T. Benson, Johanne Juel Petersen, T. Kjærgaard, Michael Pedersen","doi":"10.4081/mrm.2022.822","DOIUrl":"https://doi.org/10.4081/mrm.2022.822","url":null,"abstract":"Background Prolonged healing of tracheostomy after decannulation has a negative impact on respiration, hygiene, cosmetics, and social life. Even so, evidence-based observations of tracheostoma healing time are lacking. Therefore, the aim of this study was to determine tracheostomy wound healing time after decannulation. Methods In this prospective observational cohort study, we included 30 subjects undergoing decannulation following prolonged mechanical ventilation via tracheostomy. Our primary endpoint was tracheostomy healing time defined as time from decannulation to airtight healing. To identify any factors related to healing time, we included information about patient demographics, comorbidities, tracheostomy method, tube size, and intubation time. All subjects were observed daily until their tracheostomy wound had healed. Results The median tracheostomy healing time was 6.5 (1-22) days. The duration of tracheal cannulation was the only factor significantly correlated with prolonged healing (p=0.03). Four patients were subjected to recannulation shortly after decannulation due to hypercapnia, respiratory failure, secretion accumulation, or self-decannulation. All wounds achieved complete spontaneous airtight closure. Conclusions Duration of spontaneous tracheostomy closure after decannulation was 1-22 days, and closure time correlated with duration of cannulation.","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48521885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management dupilumab治疗2型重症哮喘的早期有效性一个由fno驱动的选择,导致成功的管理
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2022-01-12 DOI: 10.4081/mrm.2022.797
G. E. Carpagnano, G. Scioscia, E. Buonamico, D. Lacedonia, F. Diaferia, E. Capozza, G. Lepore, O. Resta, M. F. Foschino Barbaro
Background Dupilumab is a humanized monoclonal antibody targeting the IL4/IL13 signaling pathway, already used for atopic dermatitis and chronic rhinitis with nasal polyps, recently approved for severe type-2 asthma. Its efficacy has been demonstrated in randomized control trials. The aim of our study is to evaluate possible early clinical improvement and type 2 biomarkers modifications in severe asthmatic patients treated with dupilumab in a real-life setting. Methods We included 12 patients with severe, uncontrolled asthma and dupilumab was chosen if there was at least one evidence of blood eosinophils> 150 cells/ml and/or FeNO>25 ppb during last year. Recent blood eosinophil count report, assessment through ACT, FeNO test and spirometry were performed at baseline and after 3 months of treatment. We calculated also the number of patients achieving a minimal, yet clinically relevant difference in FEV1 and ACT. Results After three months of treatment with dupilumab, ACT had a significant improvement (mean ACT pre 13.25±4.65 vs mean ACT post 19.17±4.45; p<0.01), so as FEV1% (mean FEV1% pre 62.58±15.73 vs mean FEV1% post 71.00±13.11; p<0.01). FeNO had a significant reduction (median FeNO 32 pre, IQR 19-48.5 vs median FeNO19 post, IQR 16.5-26), differently from eosinophils blood count (median eosinophils pre 280, IQR 193.8-647.3 vs median eosinophils post 349.5, IQR 103-836.8; p=0.52). Four patients (33%) had a positive MCID for FEV1, and eight patients (67%) had a positive MCID for ACT. Conclusions In RCTs performed during clinical development program dupilumab showed an early efficacy in increasing FEV1, reducing FeNO and improving asthma control. Our study demonstrates early improvement in asthmatic symptoms, lung function and FeNO in severe type-2 asthma patients after only 3 months of dupilumab biologic therapy. The introduction of FeNO levels evaluation in the selection criteria for dupilumab, further helps the identification of eligible patients among type-2 severe asthma patients and allows a complete outpatient assessment. Further real-life studies with a longer follow up time will be useful to confirm dupilumab efficacy and to promote its use in clinical practice.
Dupilumab是一种靶向IL4/IL13信号通路的人源化单克隆抗体,已用于治疗特应性皮炎和慢性鼻炎伴鼻息肉,最近被批准用于治疗严重的2型哮喘。其疗效已在随机对照试验中得到证实。我们研究的目的是评估在现实环境中使用dupilumab治疗的严重哮喘患者可能的早期临床改善和2型生物标志物的改变。方法我们纳入了12例严重、未控制的哮喘患者,如果在过去一年中至少有一个证据表明血液嗜酸性粒细胞> 150细胞/ml和/或FeNO>25 ppb,则选择杜匹单抗。在基线和治疗3个月后进行近期血嗜酸性粒细胞计数报告、ACT评估、FeNO测试和肺活量测定。我们还计算了FEV1和ACT达到最小但临床相关差异的患者数量。结果:dupilumab治疗3个月后,ACT有显著改善(治疗前平均ACT为13.25±4.65 vs治疗后平均ACT为19.17±4.45;p<0.01), FEV1%(术前平均FEV1% 62.58±15.73 vs术后平均FEV1% 71.00±13.11;p < 0.01)。FeNO显著降低(feno32前中位数,IQR 19-48.5 vs FeNO19后中位数,IQR 16.5-26),不同于嗜酸性粒细胞血细胞计数(嗜酸性粒细胞280前中位数,IQR 193.8-647.3 vs嗜酸性粒细胞349.5后中位数,IQR 103-836.8;p = 0.52)。4例患者(33%)FEV1 MCID阳性,8例患者(67%)ACT MCID阳性。在临床开发项目中进行的随机对照试验中,dupilumab显示出增加FEV1、降低FeNO和改善哮喘控制的早期疗效。我们的研究表明,仅在dupilumab生物治疗3个月后,严重2型哮喘患者的哮喘症状、肺功能和FeNO均有早期改善。在dupilumab的选择标准中引入FeNO水平评估,进一步有助于在2型严重哮喘患者中识别符合条件的患者,并允许进行完整的门诊评估。进一步的现实生活研究和更长的随访时间将有助于确认dupilumab的疗效,并促进其在临床实践中的应用。
{"title":"Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management","authors":"G. E. Carpagnano, G. Scioscia, E. Buonamico, D. Lacedonia, F. Diaferia, E. Capozza, G. Lepore, O. Resta, M. F. Foschino Barbaro","doi":"10.4081/mrm.2022.797","DOIUrl":"https://doi.org/10.4081/mrm.2022.797","url":null,"abstract":"Background Dupilumab is a humanized monoclonal antibody targeting the IL4/IL13 signaling pathway, already used for atopic dermatitis and chronic rhinitis with nasal polyps, recently approved for severe type-2 asthma. Its efficacy has been demonstrated in randomized control trials. The aim of our study is to evaluate possible early clinical improvement and type 2 biomarkers modifications in severe asthmatic patients treated with dupilumab in a real-life setting. Methods We included 12 patients with severe, uncontrolled asthma and dupilumab was chosen if there was at least one evidence of blood eosinophils> 150 cells/ml and/or FeNO>25 ppb during last year. Recent blood eosinophil count report, assessment through ACT, FeNO test and spirometry were performed at baseline and after 3 months of treatment. We calculated also the number of patients achieving a minimal, yet clinically relevant difference in FEV1 and ACT. Results After three months of treatment with dupilumab, ACT had a significant improvement (mean ACT pre 13.25±4.65 vs mean ACT post 19.17±4.45; p<0.01), so as FEV1% (mean FEV1% pre 62.58±15.73 vs mean FEV1% post 71.00±13.11; p<0.01). FeNO had a significant reduction (median FeNO 32 pre, IQR 19-48.5 vs median FeNO19 post, IQR 16.5-26), differently from eosinophils blood count (median eosinophils pre 280, IQR 193.8-647.3 vs median eosinophils post 349.5, IQR 103-836.8; p=0.52). Four patients (33%) had a positive MCID for FEV1, and eight patients (67%) had a positive MCID for ACT. Conclusions In RCTs performed during clinical development program dupilumab showed an early efficacy in increasing FEV1, reducing FeNO and improving asthma control. Our study demonstrates early improvement in asthmatic symptoms, lung function and FeNO in severe type-2 asthma patients after only 3 months of dupilumab biologic therapy. The introduction of FeNO levels evaluation in the selection criteria for dupilumab, further helps the identification of eligible patients among type-2 severe asthma patients and allows a complete outpatient assessment. Further real-life studies with a longer follow up time will be useful to confirm dupilumab efficacy and to promote its use in clinical practice.","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46182898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
“Tracheostomy healing time after decannulation”: can we improve it? “气管造口术拔管后的愈合时间”:我们能改善吗?
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2022-01-12 DOI: 10.4081/mrm.2022.857
Özlem Özkan Kuşcu, D. Özcengiz, A. Esquinas
Dear Editor,We read with great interest the article “Tracheostomy healing time after decannulation” by Christiansen et al. The authors aimed to determine the tracheostomy wound healing time after decannulation... 
尊敬的编辑,我们饶有兴趣地阅读了Christiansen等人的文章《拔管后气管造口术的愈合时间》。作者旨在确定拔管后的气管造口术伤口愈合时间。。。
{"title":"“Tracheostomy healing time after decannulation”: can we improve it?","authors":"Özlem Özkan Kuşcu, D. Özcengiz, A. Esquinas","doi":"10.4081/mrm.2022.857","DOIUrl":"https://doi.org/10.4081/mrm.2022.857","url":null,"abstract":"Dear Editor,\u0000We read with great interest the article “Tracheostomy healing time after decannulation” by Christiansen et al. The authors aimed to determine the tracheostomy wound healing time after decannulation...\u0000 ","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46065227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Multidisciplinary Respiratory Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1